Trichlormethiazide

CHEMBL1054 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

380.7 g/mol

LogP

0.6

Phase

4

Trichlormethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and chloride reabsorption and increasing urinary excretion of sodium, chloride, potassium, and water. It is used for the treatment of hypertension and edematous conditions including congestive heart failure and renal disease, lowering blood pressure through initial volume reduction and later through peripheral vasodilation. Like other thiazides, it can cause hypokalemia, hyponatremia, and hyperuricemia as metabolic adverse effects.

Berat Molekul

380,7000 g/mol

LogP

0,60

TPSA

135,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O

InChI

InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)

Molecular Formula

C8H8Cl3N3O4S2

HBD / HBA

3 / 7

Ikatan yang Dapat Dirotasi

2

Atom Berat

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Trichlormethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and chloride reabsorption and increasing urinary excretion of sodium, chloride, potassium, and water. It is used for the treatment of hypertension and edematous conditions including congestive heart failure and renal disease, lowering blood pressure through initial volume reduction and later through peripheral vasodilation. Like other thiazides, it can cause hypokalemia, hyponatremia, and hyperuricemia as metabolic adverse effects.

Yes, Trichlormethiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1054. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5560. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Trichlormethiazide di PillFYI

Struktur

Data Cepat

Rumus: C8H8Cl3N3O4S2

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.